Cover Image
Market Research Report

Global Xerostomia Therapeutics Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 762828
Published Content info 112 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Xerostomia Therapeutics Market 2019-2023
Published: December 7, 2018 Content info: 112 Pages
Description

About this market

The most common disease that causes xerostomia is an inflammatory autoimmune disease. Additionally, central nervous system- related diseases including stress, depression, and anxiety can also lead to xerostomia. Moreover, trauma to the head and neck area can alter the nerve stimuli to the mouth and impair the function to the salivary glands. Therefore, the rising incidence of the health conditions or diseases that are high- risk factors for xerostomia is expected to continue to support the growth of the global xerostomia therapeutics market during the forecast period. According to our industry experts, the xerostomia therapeutics market to grow at a CAGR of over 3% during the forecast period.

Market Overview

Growing geriatric population

The increasing number of people with xerostomia is directly related to the growing geriatric population. The number of old people worldwide has been growing significantly over the years. This expected to contribute significantly to the market as this high growth in the older population helps to drive the sales of various therapeutics markets during our forecast period.

Product recalls and tedious drug approval process

Regulatory bodies have framed stringent regulations to grant marketing approval for therapeutics that are being newly developed for the treatment of xerostomia. Many applications rejected either due to the inadequate performance of the drug or because the information on the drug, which is submitted is unsatisfactory. Such stringent government regulations can lead to a delay in drug in drug approval which in turn hampers the growth of the market.

For the detailed list of factors that will drive and challenge the growth of the xerostomia therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The xerostomia therapeutics market is fragmented due to presence of many vendors in the market. The pharmaceutical companies are forming strategic collaborations which will enhance the R&D activities for new drugs for the management xerostomia. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR30455

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • OTC - Market size and forecast 2018-2023
  • Prescription - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

PART 10: VENDOR LANDSCAPE

  • Market drivers
  • Market challenges

PART 11: TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Colgate-Palmolive
  • DAIICHI SANKYO
  • Eisai
  • GlaxoSmithKline
  • ORAHEALTH

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global oral hygiene products market
  • Exhibit 03: Segments of global oral hygiene products market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: OTC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: OTC - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Prescription - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Prescription - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in Americas
  • Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in EMEA
  • Exhibit 34: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in APAC
  • Exhibit 37: Key leading countries
  • Exhibit 38: Market opportunity
  • Exhibit 39: Decision framework
  • Exhibit 01: Global prevalence of geriatric population
  • Exhibit 02: Impact of drivers and challenges
  • Exhibit 03: Biologics under development for xerostomia
  • Exhibit 04: Vendor landscape
  • Exhibit 05: Landscape disruption
  • Exhibit 06: Vendors covered
  • Exhibit 07: Vendor classification
  • Exhibit 08: Market positioning of vendors
  • Exhibit 09: Colgate-Palmolive - Vendor overview
  • Exhibit 10: Colgate-Palmolive - Business segments
  • Exhibit 11: Colgate-Palmolive - Organizational developments
  • Exhibit 12: Colgate-Palmolive - Geographic focus
  • Exhibit 13: Colgate-Palmolive - Segment focus
  • Exhibit 14: Colgate-Palmolive - Key offerings
  • Exhibit 15: Colgate-Palmolive - Key customers
  • Exhibit 16: DAIICHI SANKYO - Vendor overview
  • Exhibit 17: DAIICHI SANKYO - Organizational developments
  • Exhibit 18: DAIICHI SANKYO - Geographic focus
  • Exhibit 19: DAIICHI SANKYO - Key offerings
  • Exhibit 20: DAIICHI SANKYO - Key customers
  • Exhibit 21: Eisai - Vendor overview
  • Exhibit 22: Eisai - Business segments
  • Exhibit 23: Eisai - Organizational developments
  • Exhibit 24: Eisai - Geographic focus
  • Exhibit 25: Eisai - Segment focus
  • Exhibit 26: Eisai - Key offerings
  • Exhibit 27: Eisai - Key customers
  • Exhibit 28: GlaxoSmithKline - Vendor overview
  • Exhibit 29: GlaxoSmithKline - Business segments
  • Exhibit 30: GlaxoSmithKline - Organizational developments
  • Exhibit 31: GlaxoSmithKline - Geographic focus
  • Exhibit 32: GlaxoSmithKline - Segment focus
  • Exhibit 33: GlaxoSmithKline - Key offerings
  • Exhibit 34: GlaxoSmithKline - Key customers
  • Exhibit 35: ORAHEALTH - Vendor overview
  • Exhibit 36: ORAHEALTH - Organizational developments
  • Exhibit 37: ORAHEALTH - Key offerings
  • Exhibit 38: ORAHEALTH - Key customers
  • Exhibit 39: Validation techniques employed for market sizing
  • Exhibit 40: List of abbreviations
Back to Top